





















22. Ezeanyika, L.U.S, Ejike, C.E.C.C, Obidoa O, and Elom S.O. “Prostate disorders in an apparently normal Nigerian population 1: Prevalence”. *Biokemistri*, 2006, 18: 127-132.
23. Chokkalingam, A.P, Yeboah, E.D, DeMarzo A, Netto, G. and Yu, K., *et al.* “Prevalence of BPH and lower urinary tract symptoms in West Africans”. *Prostate Cancer Prostate Dis.*, 2012, 15: 170-176
24. South African Urological Association. Management of Benign Prostatic Hyperplasia. *SAMJ*; 2006, 96(12); 1275-1280
25. Wang, W., Guo, Y., Zhang, D. Tian, Y, Zhang, X. “The prevalence of benign prostatic hyperplasia in mainland China: evidence from epidemiological surveys”. *Sci Rep* 2015, 5, 13546.
26. Dahle, S.E, Chokkalingam, A.P, Gao, Y.T, Deng, J., Stanczyk, F.Z, *et al.* “Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia”. *J Urol*; 2002, 168:599–604.
27. Seim, A., Hoyo, C., Ostbye, T., and Vatten, L. “The prevalence and correlates of urinary tract symptoms in Norwegian men: The HUNT study”. *BJU Int.*,2005, 96: 88-92.
28. Parsons, J.K, Carter, H.B., Partin, A.W, Windham, B.G, Metter, E.J, *et al.* “Metabolic factors associated with benign prostatic hyperplasia”. *J. Clin. Endocrinol. Metab.*,2006, 91: 2562-2568
29. Gharakhanlou, R., Farzad, B., Agha-Alinejad, H., Steffen, L.M and Bayati, M. “Anthropometric measures as predictors of cardiovascular disease risk factors in the urban population of Iran”. *Arquivos Brasileiros Cardiologia*, 2012, 98: 126-135
30. Barqawi, A.B., Golden, B.K, O'Donnell, C., Brawer, M.K, Crawford, E.D. “Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program”. *Urology*; 2005, 65:708–12